OSI Seeks Partner For DPP-4 Inhibitor Paused At Phase III Gate

OSI’s metabolic business unit Prosidion also aims to out-license its glucokinase activator candidate in the next three months, Prosidion president tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet